• Wondering if DexCom at around US$61.63 is starting to look interesting again, or if the stock still carries too much downside risk for your portfolio?
• The share price has inched up about 1.7% over the past week and 0.7% over the past month, but is still down about 7.4% year to date and has declined about 27.9% over the past year.
• Recent headlines have focused on DexCom's role in continuous glucose monitoring and how that fits into broader healthcare technology trends, which can shape how investors view its growth potential. At the same time, changing sentiment around higher growth healthcare stocks has also influenced how the market prices DexCom's future prospects.
• Right now DexCom scores a 4/6 valuation check score. The next sections will walk through what different valuation approaches suggest about that number, before finishing with a broader way to think about what DexCom might be worth in your portfolio.

Approach 1: DexCom Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth today by projecting future free cash flows and discounting them back to a present value. It is essentially asking what those future cash streams are worth in current dollars.

For DexCom, the model uses a 2 Stage Free Cash Flow to Equity approach. The company’s last twelve months Free Cash Flow is about $1.42b. Analyst and extrapolated projections included in the model show Free Cash Flow reaching $1.92b in 2030, with intermediate years such as 2026 and 2027 at $993.48m and $1.24b respectively, all expressed in $. Simply Wall St applies its own methodology to extend analyst estimates out to 2035.

Bringing all of those projected cash flows back to today gives an estimated intrinsic value of about $110.52 per share. Compared with the recent share price of roughly $61.63, the DCF output suggests DexCom is 44.2% undervalued on this set of assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests DexCom is undervalued by 44.2%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Approach 2: DexCom Price vs Earnings

For profitable companies, the P/E ratio is often a useful yardstick because it links what you pay for the stock to the earnings the business is already generating. Investors usually accept a higher P/E when they expect stronger growth or see lower risk, and look for a lower P/E when growth is more modest or risks are higher.

DexCom currently trades on a P/E of about 25.6x. That is close to the Medical Equipment industry average of around 25.2x, and above the peer group average of roughly 20.4x. On the surface, that points to the stock being priced at a premium to many peers but roughly in line with the broader industry.

Simply Wall St’s Fair Ratio for DexCom is 29.5x. This is a proprietary estimate of what a "normal" P/E could look like for the company, based on factors such as its earnings growth profile, industry, profit margins, market cap and risk characteristics. Because it blends these company specific inputs rather than relying only on broad peer or industry comparisons, the Fair Ratio can offer a more tailored view of value. With the current P/E of 25.6x sitting below the Fair Ratio of 29.5x, the shares screen as undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your DexCom Narrative

Earlier the article mentioned that there is an even better way to think about value beyond ratios, and this is where Narratives come in, because a Narrative is simply your story about DexCom, tied directly to your own assumptions for future revenue, earnings and margins, that then flow through to a fair value. On Simply Wall St’s Community page, Narratives are an easy tool you can use to connect the company’s story to a forecast and then to a fair value, compare that fair value with today’s share price to decide whether DexCom looks attractive or stretched for your portfolio, and see that view refresh automatically when new information such as earnings, guidance or news is added to the platform. For example, one investor might build a DexCom Narrative closer to the more optimistic fair value of about US$112 based on stronger uptake of continuous glucose monitoring and improving margins, while another might lean toward the more cautious US$65 view that puts more weight on pricing pressure and competition, and each of those Narratives translates that story into numbers that can help inform investment decisions.

Do you think there's more to the story for DexCom? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.